(redirected from Fibrinolytic agents)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to fibrinolysis

a normal ongoing process that dissolves fibrin and results in the removal of small blood clots

References in periodicals archive ?
The most common reasons for delays in receiving fibrinolytic therapy were misdiagnosis of STEMI (including delays waiting for cardiac enzymes despite STEMI being obvious on the ECG or due to misinterpretation of the ECG), denial of fibrinolytic therapy on financial grounds in patients presenting to private hospitals, lack of familiarity with treatment protocols and inappropriate decision-making among attending doctors, especially inexperienced doctors, fear of complications, lack of urgency in administering the agents, absence of fibrinolytic agents in the emergency room or hospital, and late patient presentation (after 12 hours).
1% of patients (2 of 28) received fibrinolytic agents before percutaneous coronary intervention; the remainder underwent primary percutaneous coronary intervention.
Additional measures should include, development of written protocols at referral centers to assure a more expedite clinical assessment of patients, an enhancement of their capability for utilizing fibrinolytic agents in suitable candidates and the timely transfer to PCI-capable facilities of patients that may still benefit from catheter reperfusion.
And they were less likely to receive early therapy with aspirin, fibrinolytic agents, and [beta]-blockers, as recommended in national guidelines.
Fibrinolytic agents convert plasminogen to plasmin (fibrinolysin) that is able to break down fibrin.
Reteplase, tissue plasminogen activator (TPA), and other fibrinolytic agents only partially dissolve clot, inducing downstream microvascular embolization of atheromatous material and clot.
Fibrinolytic agents are most effective when administered within 2 to 3 hours from symptom onset (12-15) with longer treatment delays leading to worse clinical outcomes (16).
The fibrinolytic agents streptokinase and urokinase have also been used to treat acute thrombotic microangiopathy with varying success.
The first eight chapters describe the pharmacology and clinical utility of common antiplatelet, antithrombin, and fibrinolytic agents, including aspirin, the thieneopyridines, glycoprotein IIb/IIIa inhibitors, unfractionated heparin, the low-molecular weight heparins, and direct thrombin inhibitors.